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Abstract
Genderdifferencesinimmunecapabilitiessuggestthatsexhormones such as estrogenswere involved inthe regulation of the
immunocompetence. Numerous studies also suggest that plasmacytoid dendritic cells (PDCs) play a pathogenic role in SLE.
However, it is unclear whether estrogen can modulate the function of PDCs to influence the development of SLE. In the
present study, PDCs from murine spleens were treated with 17b-estradiol (E2) and CpG respectively or both in vitro, then cell
viability, costimulatory molecule expression, cytokine secretion of PDCs, as well as stimulatory capacity of PDCs to B cells were
analyzed. Results showed that E2 and CpG increased the cell viability and costimulatory molecule expression on PDCs
synergistically. Moreover, the intracellular and extracellular secretion of IFN-a was increased by E2 or E2 plus CpG. In addition,
E2 and CpG also increased the stimulatory capacity of PDCs to B cells, and the viability of B cells was decreased after
neutralizing IFN-a significantly. In the experiments in vivo, mice received daily s.c. injections of E2 and CpG respectively or
both, then we found that the plasma concentration of IgM were elevated by E2 and CpG synergistically and the expression of
IFN-a/b in spleens were noticeably increased by CpG plus E2 compared with the treatment of E2 or CpG only. This study
indicates that E2 could exacerbate PDCs’ activation with CpG, which further activates B cells to upregulate susceptibility to
autoantigens.IFN-a plays an important rolein the stimulatory effectof PDCs onB cells.E2 stimulationof IFN-a production may
result in female prevalence in autoimmune diseases such as SLE through activation of PDCs. This study provides novel
evidence of relationship between estrogen and SLE and also sheds light on gender biases among SLE patients.
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Introduction
The female prevalence in autoimmune diseases has been
recognized for over 100 years. Evidence from murine models also
showed the difference in basic immune responses between male
and female [1]. Some reports suggested that systemic lupus
erythematosus (SLE) patients experience an increase in flares
during pregnancy, possibly due to the sustained increased levels of
estrogen [2–4]. Lupus precipitated or exacerbated after com-
mencement of oral contraceptive use [5]. Lahita and Bradlow
reported that patients with SLE and their first-degree relatives had
elevated serum levels of 16 -hydroxyestrone, an actively femianiz-
ing metabolite of 17b-estradiol (E2) [6,7]. Moreover, Pisetsky et al
reported that female mice displayed high levels of circulating DNA
[8]. Our previous study showed that E2 could increase lymphocyte
apoptosis [9]. It has proved that the average length of DNA
separated from the anti-DNA antibody immune complex of SLE
blood was 180 bp, in accordance with the size of apoptosis
chromatin [10]. So scientists and physicians have suspected that
steroid hormones such as estrogen may be a key regulator of
autoimmune diseases including SLE [11].
Human and mouse plasmacytoid dendritic cells (PDCs) can
recognize CpG representing a unique microbial molecule, leading
to their activation and maturation [12,13]. PDCs have been
shown to correspond to a specialized cell population that produces
large amounts of type I interferons such as IFN-a [14]. The
production of the type I IFN by PDC in response to CpG is
mediated through TLR9 which is specific for CpG-containing
motifs [15]. On the other hand, numerous studies have suggested
that PDCs play a pathogenic role in SLE. The infiltration of PDCs
was found in the inflammatory site of SLE [16]. Recent studies
have shown that DNA-containing complexes within SLE serum
stimulate PDCs to produce IFN-a [17,18]. Many SLE patients
have increased serum levels of type I IFNs [19,20]. IFN-a levels
also correlate with anti-double-stranded DNA antibody produc-
tion, complement activation which are important indicators in
SLE disease progression [21]. In addition, a 23-year-old woman
with a metastatic carcinoma developed SLE syndrome during
IFN-a therapy [22]. These data suggested that PDC may be
participated in the development of SLE through changing IFN-a
secreting.
B cell dysfunction leading to a general B cell hypoactivity is also
a characteristic of SLE [23,24]. B cells have been thought to
contribute to lupus through the production of autoantibodies such
as anti-dsDNA antibodies [25,26]. Moreover, PDCs and CpG
license human B cells for plasma cell differentiation in the absence
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from B cells could be completely abolished by depleting PDCs
from total blood mononuclear cells [28], influenza virus-induced
type I interferon lead to polyclonal B-cell activation [29]. All these
above suggest that B cells activation and differentiation may be
mainly dependent on PDCs, but the pathways of their interaction
need to be further studied.
Our previous study showed that E2 modulated the maturation
and stimulatory functions of myeloid dendritic cells from healthy
and SLE mice [30,31]. However, it is unclear whether E2 can
influence the recognition of PDCs on CpG and the interaction
between PDCs and B cells. Therefore, in this study the response of
PDC to CpG and the stimulatory functions of PDCs to B cells
were investigated under the presence of E2 to understand the role
of estrogen in SLE.
Materials and Methods
Animals
Female BALB/c and C57B6 mice, 6–8 weeks old, were bought
from Model Animal Research Center of Nanjing University.
MRL/lpr mice in different weeks old were obtained from
Shanghai SLAC Laboratory Animal Co. LTD. They were bred
and kept under standard-pathogen-free conditions in the animal
facilities of the affiliated Drum Tower Hospital of Nanjing
University Medical School (Nanjing, China). Mice were main-
tained for at least 1 week prior to use. All animal work was
approved by the Animal Care Committee at Nanjing University.
Regents
17b-estradiol, Hepes and CFSE were purchased from Sigma
Chemical Company (St. Louis, MO, USA). IMDM and Phenol-
free RPMI 1640 were bought from Gibco. The charcoal-stripped
FCS was purchased from HyClone Laboratories (Logan, UT,
USA). FITC anti-mouse CD40, CD80, CD86, B220, IFN-a and
IgG2b, and PE anti-mouse CD19 were bought from eBioscience
Inc (San Diego, CA, USA). Cell Counting Kit 8 was bought from
Dojindo Laboratories (Japan). Mouse IFN-a EIISA Kit was
bought from PBL Biomedical Laboratories (NJ, USA). Mouse IgM
ELISA Quantitation Kit was bought from BETHYL (TX, USA).
IFN-a/b antibody for immunohistochemistry analysis were
purchased from Bioworld Company. Rat anti-mouse Interferon
Alpha antibody for neutralizing mouse interferon alpha was
purchased from PBL Biomedical Laboratories. Estradiol ELISA
Kit (Cat. No. 10–4310) was purchased from DSL Laboratories,
INC. Mouse Plasmacytoid Dendritic cell Isolation Kit, B cell
Isolation Kit and anti-Ly-6C-APC, anti-mPDCA-1-FITC were
purchased from Miltenyi Biotec (Bergisch Gladbach, Germany).
Dead Cell Discriminator (DCD) was obtained from Caltag
Laboratories. E2 was dissolved at 10 mM in water-free ethanol,
then diluted in RPMI 1640 medium to a concentration of 10 mM
stored at 220uC until use. The CpG with the sequence 59-TCC
ATG ACG TTC CTG ACG TT-39 was synthesized from
Shanghai SBS Genetech Technology Co., LTD. CpG were
dissolved in Tris-EDTA buffer and used at a final concentration of
3 mM.
Single-Cell Preparation from Mouse Spleen
Mice were immediately sacrificed and spleens were immediately
removed and placed in small culture dishes containing sterile PBS
with 10% FBS. The splenocytes were dissociated by gently
pressing the organ through a fine, sterile 30 mm-nylon mesh. The
mesh and culture dish were rinsed with medium, and then cell
suspension was collected in sterile 15 ml conical tubes. Erythro-
cytes were removed by treating the splenic cells with ACK lysing
buffer (0.15 M NH4Cl, 1.0 mM KHCO, 0.1 mM EDTA, pH 7.2)
for 4–5 min and washing twice with PBS.
Isolation of PDCs and B cells
For isolation of PDCs, single-cell suspension prepared from total
spleen was incubated for 20 min at 4uC with Biotin-Antibody
Cocktail, FcR Blocking Reagent and Anti-Biotin MicroBeads
(Miltenyi). Then the labeled cells were depleted with LS column in
order to obtain the purified PDCs. PDCs were cultured in phenol-
free RPMI-1640 supplemented with 10% FCS, 100 U ml
21
penicillin, 100 mgm l
21 streptomycin, 2 mM L-glutamine, 10 mM
Hepes and 1 mM sodium pyruvate. Similar to the isolation of
PDCs for B cells, single-cell suspension was incubated for 20 min
at 4uC with Biotin-Antibody Cocktail (CD43, CD4 and Ter119)
and Anti-Biotin MicroBeads, and then the labeled cells were
depleted with LS column in order to obtain the B cells fraction.
The purity of PDCs and B cells were determined by fluorescently
stained with anti-Ly-6C-APC, anti-mPDCA-1-FITC and anti-
CD19-PE (Figure S1 and Figure S2). The cell debris and dead cells
were excluded from the analysis based on scatter signals and DCD
fluorescence. Then all the PDCs were divided into four groups:
Control, E2 (10
28 M), CpG (3 mM) and Both (10
28 ME 2 +3 mM
CpG).
Mice Ovariectomy and E2/CpG Exposure
Thirty BALB/cJ mice were randomly divided into six groups:
Control (n=10), sham+vehicle (n=10), Ovx+vehicle (n=10),
Ovx+E2 (n=10), Ovx+CpG (n=10), Ovx+E2+CpG (n=10).
Mice were surgically ovariectomized (n=40) or sham-operated
(n=10) after anesthesia using sodium pentobarbital. All animals
were well owed to recover for two weeks and then received daily s.
c. injections of either E2 (100 mg/kg/day) or CpG (1.2 mg/Kg/
day) only or both which were dissolved in sesame oil or PBS every
morning for 2 weeks. Mice were euthanized 24 h after receiving
their last injection.
Plasma Collection and Measurement of E2 Concentration
Mice were immediately sacrificed and cardiac blood was
collected from each group or MRL mice and centrifuged at
3500 rpm. Plasma was obtained and stored at 270uC until use.
Plasma was then used to verify E2 concentration using a
commercial Estradiol EIA Kit according to the manufacturer’s
instruction. Briefly, plasma samples or E2 standards were added to
the 96-well micro titer plates coated with mouse monoclonal
antibody. Specific antibody to E2 and Tracer (acetylcholinesterase
linked to E2) were added. The plate was then covered and
incubated for 1 h at room temperature. The wells were washed
five times and added Ellman’s reagent for 60–90 min at room
temperature with gentle shaking. The plate was read at a wave
length of 412 nm.
Measurement of Immunoglobulins in the Plasma
The level of IgM and IgG in plasma was detected by mouse
IgM/IgG ELISA Quantitation kit (Bethyl Laboratories, Mon-
tgom, TX) according to the step by step protocol.
Cells Viability Assay
The cell number of every group was adjusted to 2610
5 ml
21 and
seeded into round-bottom 96-well microculture plates for 100 ml
with six parallel wells for each group. After they were cultured for
72 h, the PDCs or B cells in the wells were assayed for cell viability
by using a Cell Counting Kit-8 according to the manufacturer’s
Estrogen and PDC
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96-well plate, and the plate was pre-incubated in a humidified
incubator at 37uC, 5% CO2. Then 10 ml of the CCK-8 solution was
added to each well of the plate, and incubated for 6 h in the
incubator. At last, the cell viability was measured at the absorbance
450 nm of reduced WST-8(2-(2-methoxy-4-nitrophenyl)-3-(4-nitro-
phenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt)
using a microplate reader (Bio-Tek).
Cells Proliferation Assay
PDCs or B cells (in MLR assay) at 4610
6 cells/ml were stained
with 2 mM CFSEinpre-warmed PBS for 10 min at37uC,washed in
mediumtwice,incubatedinpre-warmedmediumforanother5 min,
and washed again. The cells then were adjusted to 1610
6 cells/ml
and cultured in medium with accordance treatment as described
above and incubated for 72 h. After 72 h cells were harvested and
washed in PBS/1% BSA/0.05% sodium azide and analyzed by flow
cytometrywithlogarithmicdetectionofagreenfluorescence(CFSE).
Events were gated to exclude the cell aggregate.
Phenotype Assay by Flow Cytometry
Purified PDCs treated with E2 and/or CpG ODN for 24 h were
washed twice in FACS medium phosphate buffered PBS containing
1%FCSand0.1%NaN3.Then thecellswereincubatedfor30 min
at 4uC with FITC-labeled CD40, CD80 and CD86 antibody
accordingtothestandardprocedure,andfollowedbyfixationin1%
paraformaldehyde. Isotype controls were used for each antibody.
Fluorescence was measured using a FACScan flow cytometry
(Becton Dickinson) and data analysis was performed using the Cell
Quest Software (Becton Dickinson, San Diego, CA).
Intracellular Cytokine Analysis by Flowcytometry
The PDCs treated with E2 and/or CpG for 24 h in the
presence of 1.7 mg/ml monensin were washed twice in PBS
containing 1% FCS and 0.1% NaN3, and then fixed in 2%
formaldehyde and permeabilized with 0.5% saponin for 20 min at
4uC respectively. Samples were washed with wash buffer
containing 0.5% saponin and then incubated with FITC labeled
IFN-a mAb for 1 h, then cells were washed with 0.5% saponin
three times and resuspended in 300 ml of 1% paraformaldehyde in
PBS. Finally, PDCs were analyzed using Cellquest Software
(Becton Dickinson, San Diego, CA, USA) as the described above.
Enzyme-Linked Immunosorbent Assay of IFN-a
ELISA kits of IFN-a were conducted according to the manufac-
ture’s protocol (RD). Briefly, every group of cells was cultured for
24 h. Then the cell culture supernatant or IFN-a standards were
added to the 96-wellmicro titer plates coated with mousemonoclonal
antibody in triplicate or duplicate, and incubated for 1 h in a closed
chamber at 24uC.Following washing once, the antibody solution was
added to each well and incubated for 24 h at 24uC. Afterwards, the
well was washed three times, HRP Conjugate solution added to each
well, and incubated for 1 h at 24uC. Following washed four times,
TMB substrate solution was added to each well and incubated for
15 minat24uC in the dark. Then the stop solution was added to each
well. At last, the absorbance was determined at 450 nm using a
microplate reader (Bio-Tek).
Preparation and Staining of Frozen Tissue Sections
The freshly isolated tissue samples including spleen and kidney
were cut into the desired number of 0.5 cm
3 pieces and then were
made into the OCT embedding compounds. The specimens were
incubated 5–10 minutes in liquid nitrogen and then stored at
280uC for long time storage. The OCT-embedded tissues were
cut to 5 mm thick sections and fixed in acetone for 5 min, then left
the slides to air dry 10 min at room temperature. After the fix step,
slides were treated with 0.3% H2O2/PBS for 5 min or until
bubbling stops in order to eliminate endogenous peroxidase
activity, and 5% standard goat serum was added to the slides for
15 min blocking. Primary antibody of IFN-a/b was diluted in
blocking buffer at the ratio of 1:100 and incubated for one night at
4uC in the humidified chamber. After washing in the PBS, sections
were incubated with the HRP labeled goat anti-rabbit second
antibody (1:50, Beyotime Institute of Biotechnology, cn.) for
30 min at 37uC in the humidified chamber. The DAB
chromogenic reagent kit (Wu Han Boster, Biological Technology.)
was used to colorate at room temperature for 1–30 minutes. The
reaction was stopped by washing with distilled water. At last, the
slides were counterstained with hematoxylin for 50 sec, washed
10 min in tap water, dehydrated through a graded series of
ethanol and transparent with xylene until sealed slides.
Allogeneic Mixed Lymphocyte Reaction (MLR In Vitro)
Functional activity of PDCs was reflected in the primary
allogeneic MLR assay. B cells as responder cells were obtained
from mouse spleen by using B cell isolation kit (Miltenyi). The
MLR assays were carried out in 96-well round-bottom microplates
to ensure efficient PDC/B cell contact. pDCs were treated with E2
and/or CpG for 24 h and then B cells were implanted with PDC
at the ratio of 1:10 (2610
4:2 610
5 per well) for 72 h in CO2
incubator (the aim of designing one ratio was that the stimulatory
capacity of this ratio is high and that it can fully reflect the
influence of E2 and CpG on this capacity of PDCs). Meanwhile, in
another parallel assay, 1 ng/ml neutralizing antibody to IFN-a
was added to the coculture system after PDCs 24 h treating, and
then cell viability and proliferation were assayed by using the
CCK-8 and CFSE separately.
Statistical Analysis
Each experiment was performed three or four times, data were
expressed as mean 6standard deviation (SD). Statistical analyses
were performed with Graphpad Prism 5.0 by using the repeated
measures ANOVA and the ANOVA post Bonferronites test.
Differences were considered statistical significant when P,0.05.
Results
E2 Influences the Cell Viability of PDCs
Activation of PDCs improves their cell counts in culture and
upregulates their expressing co-stimulatory molecules [32]. We
isolated the PDCs from the spleen of Balb/c mice and cultured
with E2, CpG respectively or both for 72 h. Our results showed
that the viability of PDCs treated with CpG or CpG+E2 were
increased especially in the group under the presence of E2 at the
same time. E2 had a moderate effect of PDCs without CpG but
had no statistical significance (Figure 1). In addition, we used the
CFSE assay to see if the PDCs had proliferation under such
treatments, and data (Figure S3) reflected no proliferation of
PDCs. These phenomena above indicated that CpG and E2
influence the viability of PDCs.
E2 Enhances the Expression of Co-Stimulatory Molecules
CD40 and CD86 on PDCs Exposed to CpG
In order to determine the activation and maturation of the
PDCs, we detected the co-stimulatory molecules expression on
them. The results showed that CpG promoted the expression of
CD40 and CD86 after 24 h. CD80 expression was also detected
Estrogen and PDC
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influenced little on co-stimulatory. However, when combination of
both E2 and CpG was used, the enhancements of CD40 and
CD86 expression were more strikingly than CpG alone (Figure 2
and Figure S4). The results suggested that E2 could enhance the
PDCs’ activation and maturation by changing the CD40 and
CD86 expression.
E2 Elevates the Intracellular and Extracellular Level of
IFN-a Produced by PDCs with the Stimulation of CpG
PDCs are professional type I IFN-producing cells upon viral
infection [33]. PDCs in SLE patients appear to be constantly
activated through TLR9 by self-chromatin-antichromatin anti-
body complexes to produce type I IFNs [34]. In order to research
the manner of which E2 and/or CpG regulate PDCs’ secretion of
IFN-a, we tested both intracellular and extracellular levels of IFN-
a after PDC was cultured for 24 h in the presence of E2 and/or
CpG (Figure 3a and Figure 3b). Results showed that E2 or CpG
could increase the level of IFN-a, while E2 plus CpG elevated the
level of IFN-a more significantly than that of E2 or CpG alone.
This suggests that E2 could enhance PDCs to express both
intracellular and extracellular IFN-a levels when the cells were
activated by CpG.
E2 Improves the Stimulatory Capacity of PDCs on B Cells
with the Activation of CpG through IFN-a
B cells activation and differentiation is dependent on PDCs [27–
29]. We designed MLR assays to test whether E2 and/or CpG
could enhance the effect of PDCs’ stimulatory capacity on B cells.
The results of CCK-8 assay showed that after co-culture with the
treated PDCs for 72 h, the viability of B cells in E2 or CpG group
was increased compared to that in control group, while the
viability was more notable in both group than in either E2 or CpG
group, and a statistical significance was observed when compared
with CpG group only (Figure 4). In the CSFE assay, we did not
observe obvious change of MFI between the different experimen-
tal groups (Figure S5). So we concluded that the data reflected B
cells viability but not proliferation. Then, we used anti-mouse IFN-
a antibody to neutralize the IFN-a in the culture supernatant, the
viability of B cells was all significantly decreased in E2, CpG and
Both groups (Figure 4). This data indicated that either E2 or CpG
could increase the stimulatory capacity of PDCs to thereby
enhance B cells’ viability. Moreover, E2 enhances the effect of
PDCs on B cells in combination with CpG, and IFN-a may play a
key role in the regulation of PDC function. We also offer the
pictures of MLR with or without neutralizing for IFN-a in order to
show the states of cell growth. The colors of cell culture
supernatant were different because of the different states of cell
growth (Figure S6 and Figure S7).
Plasma Estradiol Levels
Estradiol EIA Kit was checked and the inter-assay coefficient of
variation (CV) in ELISA was 2.77%. The results detected by
ELISA confirmed that plasma E2 concentration in Ovx+E2 group
mice was more than 4 times as much as that in virgin (control)
mice, and almost the same as that in 4 weeks old MRL mice, and
nearly the half of that in 18 weeks old MRL mice. Plasma
E2 concentrations were 8.0361.53 pg/ml (control, n=10),
8.6161.67 pg/ml (sham+vehicle, n=10), 34.0264.78 pg/ml
(Ovx+E2 n=10), 9.2861.46 pg/ml (Ovx+CpG, n=10),
35.83610.52 pg/ml (Ovx+E2+CpG, n=10), 30.03612.43 pg/
ml (4 w MRL), and 87.25617.43 pg/ml (18 w MRL), respectively
(Figure 5). E2 could not be detected in Ovx+vehicle treated group.
The normal physiological range of plasma E2 concentration in the
mouse was reported to be between 5 and 50 pg/ml [35].
Plasma IgM Levels
In order to further understand the interaction between PDCs
and B cells, we measured the immunoglobulins produced by B
cells. IgG was detected very low in all the groups, and IgM’s
secreting was obviously increased by E2, CpG and E2 plus CpG
(Figure 6). Compared with E2 or CpG only, E2 plus CpG
synergistically enhanced the IgM level in the mice plasma. This
result had a same trend as the change of E2 level in vivo and the
IFN-a secreting of PDCs.
E2 and CpG Increased the IFN-a Expression in Mouse
Spleen but Not Kidney
Since the IFN-a played a so important role in the E2 and CpG
regulation of PDCs in vitro, it is necessary to determine whether
IFN-a could expression on the spleen or kidney tissues with the
treatment of E2 and/or CpG. Meanwhile, to further understand
the biological role of type I IFN in the background of estrogen
related diseases, such as SLE, we checked the IFN-a/b expression
on the tissues from each group, and compared them with the
MRL mice tissues. The percentage and IDO (integrated optical
density) of IFN-a+ cells were analyzed using the software Image-
Pro 6.0. The results showed that the IFN-a/b expression in the
spleen of group Both were further increased compared with that in
group E2 and CpG, and that’s similar to the spleen from MRL
mice. In addition, the expression of IFN-a/b was undetected in
the kidney of every group. (Figure 7 and Figure 8)
Discussion
E2 is believed to etiology of both human and murine SLE, but
there is little knowledge about the immune state of PDCs under
the E2 environment. Recent studies have identified PDC as the
central cell type which could secret a large amount of IFN-a upon
CpG motifs, and the purified PDC but not mDC represents the
primary target for CpG. CpG increased survival, activation and
maturation of PDCs [36]. So the purified PDCs from murine
spleens were used for our studies in vitro to explain the higher
prevalence of SLE in females.
Figure 1. The viability of PDCs. The cell viability was determined by
Cell Counting Kit. The results are presented as mean 6 S.D. with
triplicate measurement. Comparisons between the different stimuli are
indicated by *, ** and ***: p,.05, .01 and .005, respectively; n=6.
doi:10.1371/journal.pone.0008412.g001
Estrogen and PDC
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8412Figure 2. The expression of co-stimulatory molecules on PDCs. The PDCs were gated to fall within established viable cell forward and side
scatter parameters and to eliminate the cell aggregates. The surface expression of costimulatory molecules CD80, CD86 and CD40 on purified pDCs
under the treatment with E2 and/or CpG in vitro were further analyzed in a FL1 density plot. Data are reported as positive PDC cells and MFI.
Histograms shown are representative of three experiments with homogenous results. Comparisons between the different stimuli are indicated by *,
** and ***: p,.05, .01 and .005, respectively; n=3.
doi:10.1371/journal.pone.0008412.g002
Estrogen and PDC
PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8412Figure 3. a The intracellular expression of IFN-a. The intracellular IFN-a expression in PDCs was analyzed by FCM, cells were gated to fall within
established viable cell forward and side scatter parameters and to eliminate the cell aggregates. Histograms shown are representative of three
experiments with homogenous results. Comparisons between the different stimuli are indicated by *, ** and ***: p,.05, .01 and .005, respectively;
n=3.b The secretion level of IFN-a. PDCs from the four groups were treated with E2/CpG separately or E2 plus CpG for 24 hours. Then the cell
culture was collected and assayed using the IFN-a ELISA Kit. The absorbance at 450 nm was read using a microplate reader (Bio-Tek). The results are
presented as mean 6 S.D. with triplicate measurement. Comparisons between the different stimuli are indicated by *, ** and ***: p,.05, .01 and .005,
respectively; n=3
doi:10.1371/journal.pone.0008412.g003
Estrogen and PDC
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activation of PDCs, we firstly test the viability and the expression
of co-stimulatory molecules on PDCs. Our results showed that E2
plus CpG could significantly increase the viability of PDCs than
CpG or E2 only. Meanwhile, the co-stimulatory molecules CD40
and CD86 were also upregulated by E2 and CpG separately or
together, but the effect of E2 on CD80 expression was minimal
compared with CD40 and CD86. These results was consistent
with the report from Anne Krug that CpG could promote survival
of PDCs, activate purified PDCs by a rapid increase of CD80,
CD86 and CD40 expression but the increased degree of CD80
was much lower than that of CD86 [37]. Amaya lparraguirre
reported that although both influenza virus and CpG led to
increased expression levels of costimulatory molecules on PDCs,
including CD40 and CD86 as well as MHC II, an exception was
CD80, which was expressed to the lower extend under the CpG
stimuli than the influenza virus stimuli [38]. This suggested us that
the costimulatory expression may be depended on different
ligands. Compared with CD11c
+ DCs, since the level of expression
of these molecules remained always lower, this seemed to suggest
that PDCs may be not good at stimulating effector cells in adaptive
immunology, and E2 may be involved in modulating the function
of PDCs with exposure to CpG.
PDC is thought to express TLR9 that is specialized to detect
intracellular pathogens such as viruses and intracellular bacteria or
parasites based on CpG motifs within their DNA. PDCs are also
the major producers of IFN-a, which plays an important role in
the clearance of viruses and other intracellular pathogens, and
have the ability to produce 100–1000 times more type I IFN than
the other blood cell types following virus activation [39]. Recent
data indicated that DNA-anti-DNA complexes in SLE sera can
provide an activation signal for IFN-a secretion [40]. It was also
shown that apoptotic cells induce PDCs to produce IFN-a [41,42].
Because of the DNA, in bacterial, virus or immune complexes can
be mimicked by synthetic CpG motifs [43], we designed the
experiment to test if E2 and CpG could aggregate PDCs activation
respectively or both through detecting the IFN-a secreting. Our
results showed that E2 plus CpG could significantly increase the
level of IFN-a compared with E2 or CpG alone. These data
suggest that PDCs are dedicated to produce much more IFN-a in
anti-nucleic acid autoimmunity under the presence of E2. So we
presume that E2 inflicts PDCs to product gross IFN-a with the
stimulation of CpG. Honda and Taniguchi reported that type I
IFN induction was mediated trough TLR signaling, which
stimulated sequential activation of adaptors and kinases of the
IRAK, IKK and TRAF families, and then leading to the
activation of IRF5 and IRF7 [44,45]. These related researches
suggested us E2 maybe change the expression of IRF5 or IRF7
through MAPK signaling pathway so as to enhance the responses
of PDCs to CpG, and eventually change the IFN-a secreting level,
we will make further studies on the possible pathways of the
interaction between E2 and CpG in our next research step.
IFN-a was found to potently enhance humoral immunity [46]
and a number of studies highlighted an important role for DCs of
Figure 4. The viability of B cells in MLR and the effect of IFN-a in
MLR. After treated with E2 and/or CpG 24 h, 1 ng/ml neutralizing
antibodies for IFN-a were added or not added to the culture system, PDCs
mixed with B cells in ratio of 1:10 for 72 h. Then cell proliferation was
determined by Cell Counting Kit. The results are presented as mean 6 S.D.
with triplicate measurement. Comparisons between the different stimuli
are indicated by *, ** and ***: p,.05, .01 and .005, respectively; n=3.
doi:10.1371/journal.pone.0008412.g004
Figure 5. The level of E2 in the plasma. After two weeks treatment
with E2 and CpG separately or together, the plasma from the different
groups was collected and tested using the Estradiol ELISA Kit. The plate
was read at a wave length of 412 nm. The results are presented as
mean 6 S.D. Comparisons between the different stimuli are indicated
by *, ** and ***: p,.05, .01 and .005, respectively; n=5.
doi:10.1371/journal.pone.0008412.g005
Figure 6. The plasma concentration of IgM. The IgM concentra-
tion was checked by Estradiol EIA Kit according to the manufacturer’s
instruction. The absorbance at 450 nm was read using a microplate
reader (Bio-Tek). The results are presented as mean 6 S.D. Comparisons
between the different stimuli are indicated by *, ** and ***: p,.05, .01
and .005, respectively; n=3.
doi:10.1371/journal.pone.0008412.g006
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factors [47] and via cell to cell contact [48]. So we further studied
the interaction of PDCs with B cells. Our results showed that
either E2 or CpG could increase the stimulatory capacity of PDCs
to thereby enhance B cells’ viability, and E2 enhanced the effect of
PDCs when coupled with CpG. Anne Krug found that PDCs
synergistically enhance activation and cytokine production of
human peripheral blood B cells that were stimulated by B-cell
receptor ligation (anti-Ig) and a microbial molecular (CpG) [36].
PDC–derived soluble factors including IFN-a contributed to B-cell
activation and increased immunoglobulin production (IgM and
IgG) of blood B cells [49]. Together with the above result that E2
and/or CpG could increase PDCs’ IFN-a secretion, we propose
that E2 activates B cells viability through promoting PDCs to
secrete more IFN-a and keeping cell-to-cell contact state. So we
used anti-mouse IFN-a mAb to neutralize the IFN-a that existed
in culture system. The result showed that the viability of B cells
was decreased after neutralizing the cytokine compared with the
groups without neutralizing IFN-a. This suggests that IFN-a is
necessary in regulating the interaction between PDCs and B cells
under the treatment of E2 with CpG.
In order to further understand the effect of E2 on PDCs and B
cells, we designed in vivo experiment that E2 and/or CpG were
injected to different groups of mice, and then the E2 concentration
and immunoglobulin production (IgM and IgG) of plasma, and
IFN-a/b expression on tissues spleen and kidney were checked.
The results showed that the E2 levels of the groups Ovx+E2 and
Ovx+E2+CpG were similar to the 4 w MRL mice and nearly 4
times more than the Control and Sham groups which in line with
our expectations. There were much more IFN-a/b expression in
mouse spleen in the Both group than either E2 or CpG group, but
IFN-a/b expression was undetected in the Control, Sham and
Ovx group. In addition, IFN-a/b expression was also undetected
in kidney. This is suggests that E2 may promote the migration of
PDCs into spleen tissue so as to lead to the elevated IFN-a/b
expression in the local region, and then the production of IgM was
increased in the plasma. It is presumed that E2 could change B
cells’ activation in exposure to CpG or bacterial or immune
complexes peptides in vivo. However, it was reported that PDCs
numbers in blood cells of SLE patients are decreased [36], it seems
contradictory with the high level of IFN-a in the sera of SLE. But
it seems important for the local concentration of IFN-a in an
affected region. According to our results IFN-a/b expressed
higher in mouse spleen in the Both group than either E2 or CpG
group, we proposed that PDCs may be recruited to lymphoid
organs or inflamed tissues under the stimuli of CpG motifs, and E2
aggravated the process of autoimmune diseases.
In conclusion, E2 and/or CpG increase the cell viability of
PDCs, and upregulate the expression of CD80, CD86 and CD40
on PDCs. E2 plus CpG also increase IFN-a secretion. In addition,
Figure 7. The expression of IFN-a/b in the spleens of mice. Immunohistochemical staining was used to detect the expression of IFN-a/b in the
spleens from mouse treated with E2 and/or CpG. The average of the percentage of IFN-a
+ cells is from more than 5 mice from each group under 406
magnification.
doi:10.1371/journal.pone.0008412.g007
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CpG. In vivo, E2 could lead to the increased IFN-a/b expression
in mouse spleens and exacerbate PDCs’ activation, which further
activated B cells to upregulate their susceptibility in producing
autoaitigens. E2 may participate in the pathogenesis of the female
prevalence in autoimmune diseases such as SLE through the
activation of PDCs.
Supporting Information
Figure S1 The purity of isolated PDCs. The purity of PDCs was
determined by fluorescently stained with Anti-mPDCA-1-FITC
and Anti-Ly-6C-APC. The cell debris and dead cells were
excluded from the analysis based on scatter signals.
Found at: doi:10.1371/journal.pone.0008412.s001 (3.71 MB TIF)
Figure S2 The purity of isolated B cells. The purity of B cells
was determined by fluorescently stained with Anti-mCD19-PE.
The cell debris and dead cells were excluded from the analysis
based on scatter signals.
Found at: doi:10.1371/journal.pone.0008412.s002 (3.32 MB TIF)
Figure S3 The proliferation assay of PDCs. PDCs were
fluorescently stained with CSFE and then treated with E2 of
CpG separately or together for 72 hours. The MFI of every group
was analyzed by flow cytometry with logarithmic detection of a
green fluorescence (CFSE). Events were gated to exclude the cell
aggregate. Green cruve: Control group; Red curve: E2 group;
Yellow curve: CpG group; Blue curve: Both Group.
Found at: doi:10.1371/journal.pone.0008412.s003 (2.42 MB TIF)
Figure S4 The expression of co-stimulatory molecules on PDCs
indicated by MFI. a) the MFI statistical chart of CD40; b) the MFI
statistical chart of CD80; c) the MFI statistical chart of CD86.
Histograms shown are representative of three experiments with
homogenous results. Comparisons between the different stimuli are
indicated by *, ** and ***: p,.05, .01 and .005, respectively; n=3.
Found at: doi:10.1371/journal.pone.0008412.s004 (5.63 MB TIF)
Figure S5 The proliferation assay of B cells in MLR. B cells
were fluorescently stained with CSFE and then mixed with treated
PDCs for 72 hours. The MFI of every group was analyzed by flow
cytometry with logarithmic detection of a green fluorescence
(CFSE). Events were gated to exclude the cell aggregate. Green
cruve: Control group; Red curve: E2 group; Yellow curve: CpG
group; Blue curve: Both Group.
Found at: doi:10.1371/journal.pone.0008412.s005 (2.45 MB TIF)
Figure S6 The cell states from neutralizing group in the MLR
test. The pictures of cells were photographed by Nikon optical
microscope and enlarged 2006 times. The colors of cell culture
supernatant from each group were different because of the
different states of cell growth.
Found at: doi:10.1371/journal.pone.0008412.s006 (2.52 MB TIF)
Figure 8. The expression of IFN-a/b in the kidney of mice. Immunohistochemical staining was used to detect the expression of IFN-a/b in the
kidneys from mouse treated with E2 and/or CpG. The average of the percentage of IFN-a
+ cells is from more than 5 mice from each group under 406
magnification.
doi:10.1371/journal.pone.0008412.g008
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test. The pictures of cells were photographed by Nikon optical
microscope and enlarged 2006 times. The colors of cell culture
supernatant from each group were different because of the
different states of cell growth.
Found at: doi:10.1371/journal.pone.0008412.s007 (2.51 MB TIF)
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